Facing Flat Erbitux Sales, ImClone Talks Up Line Extension, Pipeline Promise
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm details plans to become “global, fully integrated, pure play antibody company” during 2007 sales and earnings call.